# Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Source: https://onco.cc/trials/nct02263508/  
OnCo record `nct02263508` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Talimogene laherparepvec and Pembrolizumab in Melanoma, run by Amgen, recorded as terminated on the registry.

## Summary

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma is a phase 3 interventional study registered as NCT02263508 by Amgen, with 713 participants recorded, started 2014-12-08 and due to reach its primary completion in 2021-03-11. Interventions recorded: Talimogene Laherparepvec, Pembrolizumab, Placebo. Conditions recorded: Melanoma.

Linked to the drug Talimogene laherparepvec because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-24
- Also known as: MASTERKEY-265
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02263508
- Phase: 3
- Setting: A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)
- Sponsor: Amgen
- Enrolled: 713
- Outcomes: Phase 3: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessed Using Modified RECIST 1.1: Phase 3: Placebo + Pembrolizumab 8.5 months vs Phase 3: Talimogene Laherparepvec + Pembrolizumab 14.3 months, HR 0.86; Phase 1b: Objective Response Rate (ORR): Phase 1b: Talimogene Laherparepvec + Pembrolizumab 61.9%

## Sources

- ClinicalTrials.gov NCT02263508: https://clinicaltrials.gov/study/NCT02263508

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Talimogene laherparepvec](https://onco.cc/drugs/talimogene-laherparepvec/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct02263508.json